Use of ACTIMMUNE in Patients With ADO2

计划入组 12 人 · 首次发布于 2015 年 10 月 22 日

Biomarkers in Autosomal Dominant Cerebellar Ataxia

计划入组 102 人 · 首次发布于 2011 年 11 月 11 日

Natural History of Autosomal Dominant Hearing Loss

计划入组 1,100 人 · 首次发布于 2020 年 8 月 6 日

autosomal dominant polycystic kidney disease therapeutics

Autosomal dominant polycystic kidney disease(Maze Therapeutics)

autosomal dominant polycystic kidney disease therapy, Healx

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

āshibio Licenses Vantictumab for Rare Bone Disease ADO2 in Strategic Pipeline Expansion

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for Alvelestat in AATD-LD

GSK Receives FDA Orphan Drug Designation for Autosomal Dominant Polycystic Kidney Disease Treatment